mpges1 inhibitor

CAY10526 (BTH) is a selective mPGES-1 inhibitor that acts as an inhibitor of the NF-κB signaling pathway.

mPGES-1 Inhibitor-1 is a novel selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1) with anti-inflammatory and analgesic activity for the study of acute liver injury.

mPGES1-IN-3 is a potent and selective inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1) .

mPGES1-IN-4 (compound 32) is a multi-substituted pyrimidine compound acting as a submicromolar inhibitor of PGE2 production. It primarily exerts its anti-inflammatory effects by inhibiting mPGES-1 and significantly suppresses acute inflammation models in vivo.

mPGES1-IN-5 (compound 18) is a multi-substituted pyrimidine compound that acts as a submicromolar inhibitor of PGE2 production. It primarily exerts its anti-inflammatory effects by inhibiting mPGES-1 and demonstrates significant inhibitory activity in vivo against acute inflammation models.

mPGES1-IN-9 (compound 1_8) is an mPGES1 inhibitor with an IC50 of 0.5 μM and is utilized in anti-inflammatory research.

mPGES1-IN-10 (Compound 7d) is a potent inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1) with an IC50 value of 1.0 μM. It holds potential for research into chronic inflammation-related diseases and malignant tumors, such as colorectal cancer.